Table 5. Relative risk of soft-tissue and bone cancer, colorectal cancer, and breast cancer as a function of the cumulative 131I activity administered 2 years or more before the diagnosis of SPMs.
|
Number of SPMs and RRa (95% CI) |
||||||
|---|---|---|---|---|---|---|
| Amount of 131I (GBq) | Soft-tissue and bone cancer | Colorectal cancer | Breast cancer | |||
| ⩽0.2 | 5 | 1 (ref) | 32 | 1 (ref) | 74 | 1 (ref) |
| [0.2–3.6] | 5 | 2.9 (0.8–10.7) | 12 | 0.9 (0.5–1.8) | 23 | 0.9 (0.5–1.4) |
| [3.7–7.3] | 4 | 3.4 (0.8–13.3) | 13 | 1.1 (0.6–2.2) | 19 | 0.6 (0.3–1.0) |
| [7.4–14.7] | 3 | 7.7 (1.5–33.3) | 8 | 2.5 (1.0–5.5) | 9 | 1.0 (0.4–1.9) |
| ⩾14.8 | 2 | 13.0 (1.7–67.1) | 4 | 3.2 (0.9–8.7) | 3 | 0.9 (0.2–2.5) |
a
Relative risk adjusted on external radiotherapy and stratified on study group.